However, in many types of cancers, including breast, prostate, lung, colorectal, and ovarian cancers, FAS is dramatically upregulated not only to support the rapid progression but also closely involved with aggressive tumor phenotypes and correlated with poor clinical outcomes (Menendez and Lupu, 2007; Esslimani-Sahla et al., 2007). This evidence concerns the gene FAS and neoplasm.